Safety, tolerability, and immunogenicity of a CpG/Alum adjuvanted SARS-CoV-2 recombinant protein vaccine (ZR202-CoV) in healthy adults: Preliminary report of a phase 1, randomized, double-blind, placebo-controlled, dose-escalation trial
CpG/明矾佐剂SARS-CoV-2重组蛋白疫苗(ZR202-CoV)在健康成人中的安全性、耐受性和免疫原性:一项1期随机、双盲、安慰剂对照、剂量递增试验的初步报告
期刊:Human Vaccines & Immunotherapeutics
影响因子:3.5
doi:10.1080/21645515.2023.2262635
Feng, Guang-Wei; Wang, Zhong-Fang; He, Peng; Lan, Qin-Ying; Ni, Ling; Yang, Ya-Zheng; Wang, Chen-Fei; Cui, Ting-Ting; Huang, Li-Li; Yan, Yong-Qiang; Jiang, Zhi-Wei; Yang, Qing; Yu, Bang-Wei; Han, Xi; Chen, Jing-Jing; Yang, Shu-Yuan; Yuan, Lin; Zhou, Ling-Yun; Liu, Ge; Li, Ke; Huang, Zhen; Zhao, Jin-Cun; Hu, Zhong-Yu; Xie, Zhi-Qiang